Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape cancer ...

The results of a late-stage drug trial released Thursday are raising hopes that type 1 diabetes patients with chronic kidney ...

Renal cell carcinoma (RCC) comprises a heterogeneous group of neoplasms with variable prognoses. Chromophobe RCC, a relatively uncommon subtype, generally follows an indolent clinical course but may ...

A rapid multidisciplinary approach is needed to reduce serum free light chain levels and restore kidney function ...

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 ...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor ...

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced ...

REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the third quarter ended September 30, 2025 and provided an overview ...

Percutaneous cryoablation yields outcomes comparable to robotic surgery for renal cancer, at significantly lower cost, Danish ...

In late September, oncology experts gathered in Nashville, Tennessee, for the 2025 Patient-Centered Oncology Care ® conference. Over 2 days, 15 panel discussions explored topics aligned with this year ...

The awards were made possible by ongoing support from the Blavatnik Family Foundation that aims to spur scientific ...

On 5 November 2025, the 8th China International Import Expo (CIIE) opened at the National Exhibition and Convention Center (Shanghai). As a "full-attendance" exhibitor for eight consecutive years, ...